Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2018

View Archived Issues

Prestige Biopharma recruiting healthy males subjects in PK equivalency study

Keeping trash disposal working protects mice from asthma

RBM-007 could be a treatment for achondroplasia

Immunotherapy with T cells targeting claudin 18.2 are effective and safe in gastric cancer

Long noncoding RNA LNMAT1 promotes bladder cancer metastasis

FABP4 seen to regulate ovarian cancer metastasis

Quinoline-based tracers targeting FAP show theranostic potential

Collaboration to evaluate preclinical safety and feasibility of InVivo's Neuro-Spinal Scaffold with

First clinical data presented for nifedipine in patients with hyperinsulinemic hypoglycemia

Phase III studies of Lilly's Ultra Rapid Lispro in diabetes meet primary efficacy endpoint

Clementia begins phase I trial with palovarotene eye drop formulation

Cellectar updates OS data from phase Ib trial of CLR-131 in relapsed or refractory multiple myeloma

FDA approves Seysara for acne

Antisense spherical nucleic acids proven useful for treating IBD in mice

Phase III IMPLANT 2 results show nolasiban improves live birth rate in women undergoing IVF

FDA approves Nuzyra for CABP and ABSSSI

Phase IIb study of VBP-926 in chemotherapy-associated paronychia meets primary endpoint

Sobi reports phase II primary efficacy results for anakinra in acute gout

Medshine Discovery and Fujian Cosunter Pharmaceutical patent compounds for HBV

SIMM synthesizes new PRMT5 inhibitors

Truly Translational Sweden identifies new sulfasalazine prodrugs

Palobiofarma presents adenosine A1 receptor antagonists

Bionomics' phase II trial of BNC-210 in PTSD does not meet primary endpoint

Takeda Pharmaceutical patents orexin OX2 receptor agonists